Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 3
2012 3
2013 1
2014 1
2016 2
2017 4
2018 5
2019 7
2020 2
2021 7
2022 9
2023 7
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z, Orlowski RZ; IMROZ Study Group. Facon T, et al. N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3. N Engl J Med. 2024. PMID: 38832972 Clinical Trial.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, Patel V, Kaur P, Barr H, Lee DJ, Lightbody E, Downey K, Argyelan D, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Chavda SJ, Ainley L, Sandecká V, Pospíšilová L, Minarik J, Jungova A, Radocha J, Spicka I, Nadeem O, Yong K, Hájek R, Kastritis E, Marinac CR, Dimopoulos MA, Get G, Trippa L, Ghobrial IM. Cowan A, et al. Among authors: jungova a. Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6. Lancet Haematol. 2023. PMID: 36858677 Free PMC article.
Severe Hyperkalemia in a Hematology-Oncology Patient.
Racek J, Rajdl D, Jungová A. Racek J, et al. Among authors: jungova a. Clin Chem. 2019 Feb;65(2):354-355. doi: 10.1373/clinchem.2018.290387. Clin Chem. 2019. PMID: 30692139 No abstract available.
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data.
Maisnar V, Pour L, Spicka I, Jelinek T, Minarik J, Jungova A, Stork M, Straub J, Radocha J, Pika T, Pospisilova L, Nair S, Kunovszki P, Hajek R. Maisnar V, et al. Among authors: jungova a. Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):145-153. doi: 10.1016/j.clml.2022.11.001. Epub 2022 Nov 6. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36567210
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.
Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, Stork M, Pour L, Pavlicek P, Spicka I, Maisnar V, Radocha J, Simicek M, Hajek R. Jelinek T, et al. Among authors: jungova a. Leukemia. 2022 Jan;36(1):288-291. doi: 10.1038/s41375-021-01343-w. Epub 2021 Jul 10. Leukemia. 2022. PMID: 34247197 No abstract available.
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Stork M, Spicka I, Radocha J, Minarik J, Jelinek T, Jungova A, Pavlicek P, Pospisilova L, Sedlak F, Straub J, Pika T, Knechtova Z, Fidrichova A, Boichuk I, Sevcikova S, Maisnar V, Hajek R, Pour L. Stork M, et al. Among authors: jungova a. Ann Hematol. 2023 Jun;102(6):1501-1511. doi: 10.1007/s00277-023-05188-4. Epub 2023 Apr 24. Ann Hematol. 2023. PMID: 37088816 Free PMC article.
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.
Zátopková M, Ševčíková T, Fanfani V, Chyra Z, Říhová L, Bezděková R, Žihala D, Growková K, Filipová J, Černá L, Broskevičova L, Kryukov F, Minařík J, Smejkalová J, Maisnar V, Harvanová Ĺ, Pour L, Jungova A, Popková T, Bago JR, Anilkumar Sithara A, Hrdinka M, Jelínek T, Šimíček M, Stracquadanio G, Hájek R. Zátopková M, et al. Among authors: jungova a. Blood Adv. 2022 Jan 25;6(2):368-372. doi: 10.1182/bloodadvances.2020003876. Blood Adv. 2022. PMID: 34500459 Free PMC article. No abstract available.
45 results